PlainPharmaWatch

CMS Open Payments · Tool

LeMaitre Vascular, Inc. vs kaleo, Inc.

Side-by-side comparison of CMS Open Payments data for Program Year 2024. Select different companies below to start a new comparison.

A larger reported total is not "better" or "worse", it is a neutral fact about disclosure volume; a reported payment documents a financial relationship, not evidence of wrongdoing.

Compare Different Companies

vs

Relationship comparison

Which recorded payment profile is more concentrated?

LeMaitre Vascular, Inc. has the more concentrated recorded General Payments recipient profile in Program Year 2024: its recipient-distribution HHI is 1,805, versus 243 for the other company. Its single largest recorded recipient represents 41.1% of that company's General Payments recipient total.

HHI summarizes how payments are distributed across recorded recipients: higher means a less evenly distributed recipient pattern. This is a description of CMS-reported General Payments only, not a finding about conduct, prescribing, quality, or wrongdoing. Read it with the recipient count and underlying records below.

LeMaitre Vascular, Inc.
HHI 1,805 · top recipient 41.1%
Ranked #786 of 1,838 companies by HHI
kaleo, Inc.
HHI 243 · top recipient 7.5%
Ranked #1,517 of 1,838 companies by HHI

Payment Overview

Total Payments
$311.5K
% of Industry
0.0%
Transactions
2,946
Avg per Transaction
$105.74
Recipients
2,946
Avg per Recipient
$105.74
Payment Types
4
Top Payment Type
Consulting Fee
Company B

kaleo, Inc.

Total Payments
$313.0K
% of Industry
0.0%
Transactions
6,334
Avg per Transaction
$49.42
Recipients
6,327
Avg per Recipient
$49.47
Payment Types
5
Top Payment Type
Food and Beverage

Highlighted values indicate the higher figure for each metric.

Total payments compared

LeMaitre Vascular, Inc. vs kaleo, Inc. - total reported payments in CMS Open Payments PY2024

kaleo, Inc.$313.0KLeMaitre Vascular, Inc.$311.5K

General Payment Types Breakdown

Category shares use each company's General Payments total, not the all-tracks (General + Research + Ownership) hero figure.

LeMaitre Vascular, Inc.

Consulting Fee $215.6K

69.2%

Food and Beverage $95.1K

30.5%

Education $742.00

0.2%

Travel and Lodging $74.93

0.0%

kaleo, Inc.

Food and Beverage $141.4K

55.1%

Consulting Fee $43.6K

17.0%

Compensation for Services Other Than Consulting $42.2K

16.5%

Travel and Lodging $26.4K

10.3%

Space Rental or Facility Fees $3.0K

1.2%

Top 5 General-Payment Recipients

This list uses CMS detailed General Payments records only; it excludes research and ownership/investment records, so it does not equal the all-category totals above. A reported payment documents a financial relationship, not evidence of wrongdoing; a higher total reflects reporting volume, not conduct. Verify directly at openpaymentsdata.cms.gov.

LeMaitre Vascular, Inc.

  1. 1

    MARK KELDAHL

    $128,088.57 · 14 txns

  2. 2

    MICHAEL LIEB

    $20,691.30 · 21 txns

  3. 3

    WILLIAM EDWARD RAIBLE III

    $18,224.83 · 30 txns

  4. 4

    GEORGE J KOULLIAS

    $8,920.40 · 2 txns

  5. 5

    CHRISTOPHER R KINTER

    $7,824.32 · 7 txns

kaleo, Inc.

  1. 1

    JOYCE RABBAT

    $19,230.74 · 19 txns

  2. 2

    SUSAN LAUBACH

    $18,427.71 · 19 txns

  3. 3

    RUCHI GUPTA

    $16,671.38 · 3 txns

  4. 4

    ROXANNE CARBONELL ORIEL

    $15,284.07 · 21 txns

  5. 5

    JEREMY SIKORA

    $13,048.87 · 25 txns

Summary Comparison

Metric LeMaitre Vascular, Inc. kaleo, Inc.
Total Payments $311.5K $313.0K
% of Industry Total 0.0% 0.0%
Transaction Count 2,946 6,334
Avg per Transaction $105.74 $49.42
Recipient Count 2,946 6,327
Avg per Recipient $105.74 $49.47
Payment Type Count 4 5
Top Payment Type Consulting Fee Food and Beverage

Data Source: Centers for Medicare & Medicaid Services (CMS) Open Payments, Program Year 2024. Data includes general payments, research payments, and physician ownership/investment interests as required by the Physician Payments Sunshine Act. All companies in the CMS Open Payments company corpus are available in the selector. Browse all companies →

Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.